Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Weaver
Vanderbilt University, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
WaveFront Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Description of how the financial interest relates to the funded research: Dr. Weaver is an owner of WaveFront Biosciences. The Wavefront product, the Panoptic plate reader, is used heavily in the research supported by the grant. In addition, at some point between now and the end of the grant Thallos, a reagent used heavily in the research funded by the grant, may be sold by Wavefront as the sole provider of Thallos.
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator
G protein-gated Inwardly-Rectifying potassium (K+)-selective (GIRK) ion channels are critical determinants of excitability in the heart and brain, and have been implicated in normal and disease-related processes including anxiety, seizures, pain perception, and heart rate regulation. Defining precise physiological and pathophysiological roles for GIRK channels has been difficult due to the existence of multiple channel subtypes and the lack of subtype-selective pharmacological tools that could be used to study the channels in in vivo settings. The goal of this research project is to develop selective activators for the most prevalent neuronal GIRK channel subtype, and then to begin applying these tools toward rigorous investigations into the relevance and therapeutic potential of this intriguing brain targe.
Filed on March 09, 2017.
Tell us what you know about David Weaver's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Weaver filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | $5,000 - $9,999 |
| David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | $0 - $4,999 |
| David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.